Not known Facts About YX-2-107
MI-CP151 was a period 1b randomised, double-blind, placebo managed, dose-escalation, multicentre review to evaluate various intravenous doses of sifalimumab, in adult patients with dermatomyositis or polymyositis (NCT00533091). Key trial aims were being To guage the protection and tolerability of sifalimumab in dermatomyositis or polymyositis peopl